Income statement, balance sheet and cash flow are strong.
Next earnings: 2026-10-29 (BMO), EPS Forecast: ($4.27)
Upgraded from Hold to Buy in the Mar 2026 quarter: 74.2 → 80.9 (+6.7). This quarter: +0.0.
Change vs previous quarter.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.